Answers are grounded in this paper and cite their sources.
Sorafenib is one of the most effective agent used in the systemic treatment of hepatocellular carcinoma (HCC); however, patients often develop resistance to sorafenib over time, thereby limiting its therapeutic efficacy. Potential efficacy of combined treatment of regorafenib with Nrf2 inhibitors in sorafenib-resistant HCC cells remains unclear. Therefore, in this study, we investigated whether inhibition of the Nrf2 pathway could enhance the anticancer activity of regorafenib in sorafenib-resistant HCC cell lines. In HuH-7 SorRes cells, IC 50 values following regorafenib treatment were 4.9-fold and 2-fold higher at 48 and 72 h, respectively, compared to parental HuH-7 cells. Similar resistance patterns were observed in Mahlavu SorRes cells. Western blot analysis revealed upregulation of Nrf2 expression in HuH-7 SorRes cells. Suppression of the Nrf2 pathway in HuH-7 SorRes cells resulted in a significant reduction in cell viability and ERK1/2 phosphorylation, along with increased cleaved caspase-3 expression, elevated intracellular reactive oxygen species levels, and decreased cell migration. Furthermore, in 3D tumor spheroid models, regorafenib significantly inhibited spheroid growth in HuH-7 SorRes cells under Nrf2-suppressed conditions. In conclusion, our study demonstrated that HCC cells which developed resistance to sorafenib also exhibited resistance to regorafenib, and this resistance could be overcome by inhibition of the Nrf2 signaling pathway.
No takes yet. Share an insight, caveat, or question.
Kahraman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: